TY - JOUR AU - Agha, A. AU - Tarhini, A. A. PY - 2017 DA - 2017// TI - Adjuvant therapy for melanoma JO - Curr Oncol Rep VL - 19 UR - https://doi.org/10.1007/s11912-017-0594-5 DO - 10.1007/s11912-017-0594-5 ID - Agha2017 ER - TY - JOUR AU - Nishikawa, H. AU - Sakaguchi, S. PY - 2014 DA - 2014// TI - Regulatory T cells in cancer immunotherapy JO - Curr Opin Immunol VL - 27 UR - https://doi.org/10.1016/j.coi.2013.12.005 DO - 10.1016/j.coi.2013.12.005 ID - Nishikawa2014 ER - TY - JOUR AU - Balch, C. M. AU - Soong, S. J. AU - Gershenwald, J. E. AU - Thompson, J. F. AU - Reintgen, D. S. AU - Cascinelli, N. PY - 2001 DA - 2001// TI - Prognostic factors analysis of 17,600 melanoma patients: validation of the American Joint Committee on cancer melanoma staging system JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.16.3622 DO - 10.1200/JCO.2001.19.16.3622 ID - Balch2001 ER - TY - JOUR AU - Ugel, S. PY - 2012 DA - 2012// TI - Immune tolerance to tumor antigens occurs in a specialized environment of the spleen JO - Cell Rep. VL - 2 UR - https://doi.org/10.1016/j.celrep.2012.08.006 DO - 10.1016/j.celrep.2012.08.006 ID - Ugel2012 ER - TY - JOUR AU - Balch, C. M. AU - Urist, M. M. AU - Karakousis, C. P. AU - Smith, T. J. AU - Temple, W. J. AU - Drzewiecki, K. PY - 1993 DA - 1993// TI - Efficacy of 2-cm surgical margins for intermediate-thickness melanomas JO - Ann Surg VL - 218 UR - https://doi.org/10.1097/00000658-199309000-00005 DO - 10.1097/00000658-199309000-00005 ID - Balch1993 ER - TY - JOUR AU - Balch, C. M. AU - Soong, S. J. AU - Smith, T. AU - Ross, M. I. AU - Urist, M. M. AU - Karakousis, C. P. PY - 2001 DA - 2001// TI - Long-term results of a prospective surgical trial comparing 2 cm vs. 4 cm excision JO - Ann Surg Oncol VL - 8 ID - Balch2001 ER - TY - JOUR AU - Karakousis, C. P. AU - Balch, C. M. AU - Urist, M. M. AU - Ross, M. M. AU - Smith, T. J. AU - Bartolucci, A. A. PY - 1996 DA - 1996// TI - Local recurrence in malignant melanoma: long-term results of the multiinstitutional randomized surgical trial JO - Ann Surg Oncol VL - 3 UR - https://doi.org/10.1007/BF02305762 DO - 10.1007/BF02305762 ID - Karakousis1996 ER - TY - JOUR AU - Kirkwood, J. M. AU - Ibrahim, J. G. AU - Sosman, J. A. AU - Sondak, V. K. AU - Agarwala, S. S. AU - Ernstoff, M. S. PY - 2001 DA - 2001// TI - High-dose interferon alfa-2b significantly prolongs relapse-free and overall survival compared with the GM2-KLH/QS-21 vaccine in patients with resected stage IIB-III melanoma: results of intergroup trial E1694/S9512/C509801 JO - J Clin Oncol VL - 19 UR - https://doi.org/10.1200/JCO.2001.19.9.2370 DO - 10.1200/JCO.2001.19.9.2370 ID - Kirkwood2001 ER - TY - JOUR AU - Kirkwood, J. M. AU - Strawderman, M. H. AU - Ernstoff, M. S. AU - Smith, T. J. AU - Borden, E. C. AU - Blum, R. H. PY - 1996 DA - 1996// TI - Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684 JO - J Clin Oncol VL - 14 UR - https://doi.org/10.1200/JCO.1996.14.1.7 DO - 10.1200/JCO.1996.14.1.7 ID - Kirkwood1996 ER - TY - JOUR AU - Kirkwood, J. M. AU - Ibrahim, J. G. AU - Sondak, V. K. AU - Richards, J. M. AU - Flaherty, L. E. AU - Ernstoff, M. S. PY - 2000 DA - 2000// TI - High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190 JO - J Clin Oncol VL - 18 UR - https://doi.org/10.1200/JCO.2000.18.12.2444 DO - 10.1200/JCO.2000.18.12.2444 ID - Kirkwood2000 ER - TY - JOUR AU - Schadendorf, D. AU - Hodi, F. S. AU - Robert, C. AU - Weber, J. S. AU - Margolin, K. AU - Hamid, O. PY - 2015 DA - 2015// TI - Pooled analysis of long-term survival data from phase II and phase III trials of ipilimumab in unresectable or metastatic melanoma JO - J Clin Oncol VL - 33 UR - https://doi.org/10.1200/JCO.2014.56.2736 DO - 10.1200/JCO.2014.56.2736 ID - Schadendorf2015 ER - TY - JOUR AU - Eggermont, A. M. M. AU - Chiarion-Sileni, V. AU - Grob, J. J. AU - Dummer, R. AU - Wolchok, J. D. AU - Schmidt, H. AU - Hamid, O. AU - Robert, C. AU - Ascierto, P. A. AU - Richards, J. M. AU - Lebbé, C. AU - Ferraresi, V. AU - Smylie, M. AU - Weber, J. S. AU - Maio, M. AU - Bastholt, L. AU - Mortier, L. AU - Thomas, L. AU - Tahir, S. AU - Hauschild, A. AU - Hassel, J. C. AU - Hodi, F. S. AU - Taitt, C. AU - Pril, V. AU - Schaetzen, G. AU - Suciu, S. AU - Testori, A. PY - 2016 DA - 2016// TI - Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy JO - N Engl J Med VL - 375 UR - https://doi.org/10.1056/NEJMoa1611299 DO - 10.1056/NEJMoa1611299 ID - Eggermont2016 ER - TY - JOUR AU - Hodi, F. S. AU - O’Day, S. J. AU - McDermott, D. F. AU - Weber, R. W. AU - Sosman, J. A. AU - Haanen, J. B. PY - 2010 DA - 2010// TI - Improved survival with ipilimumab in patients with metastatic melanoma JO - N Engl J Med VL - 363 UR - https://doi.org/10.1056/NEJMoa1003466 DO - 10.1056/NEJMoa1003466 ID - Hodi2010 ER - TY - JOUR AU - Waterhouse, P. AU - Penninger, J. M. AU - Timms, E. AU - Wakeham, A. AU - Shahinian, A. AU - Lee, K. P. PY - 1995 DA - 1995// TI - Lymphoproliferative disorders with early lethality in mice deficient in Ctla-4 JO - Science VL - 270 UR - https://doi.org/10.1126/science.270.5238.985 DO - 10.1126/science.270.5238.985 ID - Waterhouse1995 ER - TY - JOUR AU - Karandikar, N. J. AU - Vanderlugt, C. L. AU - Walunas, T. L. AU - Miller, S. D. AU - Bluestone, J. A. PY - 1996 DA - 1996// TI - CTLA-4: a negative regulator of autoimmune disease JO - J Exp Med VL - 184 UR - https://doi.org/10.1084/jem.184.2.783 DO - 10.1084/jem.184.2.783 ID - Karandikar1996 ER - TY - JOUR AU - Read, S. AU - Malmström, V. AU - Powrie, F. PY - 2000 DA - 2000// TI - Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation JO - J Exp Med VL - 192 UR - https://doi.org/10.1084/jem.192.2.295 DO - 10.1084/jem.192.2.295 ID - Read2000 ER - TY - JOUR AU - Wing, K. AU - Onishi, Y. AU - Prieto-Martin, P. AU - Yamaguchi, T. AU - Miyara, M. AU - Fehervari, Z. PY - 2008 DA - 2008// TI - CTLA-4 control over Foxp3+ regulatory T cell function JO - Science VL - 322 UR - https://doi.org/10.1126/science.1160062 DO - 10.1126/science.1160062 ID - Wing2008 ER - TY - JOUR AU - Nishikawa, H. AU - Sakaguchi, S. PY - 2010 DA - 2010// TI - Regulatory T cells in tumor immunity JO - Int J Cancer VL - 127 ID - Nishikawa2010 ER - TY - JOUR AU - Tarhini, A. A. AU - Edington, H. AU - Butterfield, L. H. AU - Lin, Y. AU - Shuai, Y. PY - 2014 DA - 2014// TI - Immune monitoring of the circulation and the tumor microenvironment in patients with regionally advanced melanoma receiving neoadjuvant ipilimumab JO - PLoS ONE VL - 9 UR - https://doi.org/10.1371/journal.pone.0087705 DO - 10.1371/journal.pone.0087705 ID - Tarhini2014 ER - TY - JOUR AU - Mandapathil, M. AU - Lang, S. AU - Gorelik, E. AU - Whiteside, T. L. PY - 2009 DA - 2009// TI - Isolation of functional human regulatory T cells (Treg) from the peripheral blood based on the CD39 expression JO - J Immunol Methods VL - 346 UR - https://doi.org/10.1016/j.jim.2009.05.004 DO - 10.1016/j.jim.2009.05.004 ID - Mandapathil2009 ER - TY - JOUR AU - Schuler, P. J. AU - Harasymczuk, M. AU - Schilling, B. AU - Lang, S. AU - Whiteside, T. L. PY - 2011 DA - 2011// TI - Separation of human CD4+CD39+ T cells by magnetic beads reveals two phenotypically and functionally different subsets JO - J Immunol Methods VL - 369 UR - https://doi.org/10.1016/j.jim.2011.04.004 DO - 10.1016/j.jim.2011.04.004 ID - Schuler2011 ER - TY - JOUR AU - Schuler, P. J. AU - Schilling, B. AU - Harasymczuk, M. AU - Hoffmann, T. K. AU - Johnson, J. AU - Lang, S. PY - 2012 DA - 2012// TI - Phenotypic and functional characteristics of CD4+CD39+FOXP3+ and CD4+CD39+FOXP3neg T-cell subsets in cancer patients JO - Eur J Immunol VL - 42 UR - https://doi.org/10.1002/eji.201142347 DO - 10.1002/eji.201142347 ID - Schuler2012 ER - TY - JOUR AU - Nishikawa, H. AU - Sakaguchi, S. PY - 2014 DA - 2014// TI - Regulatory T cells in cancer immunotherapy JO - Cur Opin Immunol VL - 27 UR - https://doi.org/10.1016/j.coi.2013.12.005 DO - 10.1016/j.coi.2013.12.005 ID - Nishikawa2014 ER - TY - JOUR AU - Gray, C. P. AU - Arosio, P. AU - Hersey, P. PY - 2003 DA - 2003// TI - Association of increased levels of heavy-chain ferritin with increased CD4+CD25+ regulatory T-cell levels in patients with melanoma JO - Clin Cancer Res VL - 9 ID - Gray2003 ER - TY - JOUR AU - McCarter, M. D. AU - Baumgartner, J. AU - Escobar, G. A. AU - Richter, D. AU - Lewis, K. AU - Robinson, W. PY - 2007 DA - 2007// TI - Immunosuppressive dendritic and regulatory T cells are upregulated in melanoma patients JO - Ann Surg Oncol VL - 14 UR - https://doi.org/10.1245/s10434-007-9488-3 DO - 10.1245/s10434-007-9488-3 ID - McCarter2007 ER - TY - JOUR AU - Phan, G. Q. AU - Yang, J. C. AU - Sherry, R. M. AU - Hwu, P. AU - Topalian, S. L. AU - Schwartzentruber, D. J. PY - 2003 DA - 2003// TI - Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma JO - Proc Natl Acad Sci USA VL - 100 UR - https://doi.org/10.1073/pnas.1533209100 DO - 10.1073/pnas.1533209100 ID - Phan2003 ER - TY - JOUR AU - Sarnaik, A. A. AU - Yu, B. AU - Yu, D. AU - Morelli, D. AU - Hall, M. AU - Bogle, D. PY - 2011 DA - 2011// TI - Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma JO - Clin Cancer Res VL - 17 UR - https://doi.org/10.1158/1078-0432.CCR-10-2463 DO - 10.1158/1078-0432.CCR-10-2463 ID - Sarnaik2011 ER - TY - JOUR AU - Weber, J. S. AU - O’Day, S. AU - Urba, W. AU - Powderly, J. AU - Nichol, G. AU - Yellin, M. PY - 2008 DA - 2008// TI - Phase I/II study of ipilimumab for patients with metastatic melanoma JO - J Clin Oncol VL - 26 UR - https://doi.org/10.1200/JCO.2008.16.1927 DO - 10.1200/JCO.2008.16.1927 ID - Weber2008 ER - TY - JOUR AU - Maker, A. V. AU - Attia, P. AU - Rosenberg, S. A. PY - 2005 DA - 2005// TI - Analysis of the cellular mechanism of antitumor responses and autoimmunity in patients treated with CTLA-4 blockade JO - J Immunol VL - 175 UR - https://doi.org/10.4049/jimmunol.175.11.7746 DO - 10.4049/jimmunol.175.11.7746 ID - Maker2005 ER - TY - JOUR AU - Menard, C. AU - Ghiringhelli, F. AU - Roux, S. AU - Chaput, N. AU - Mateus, C. AU - Grohmann, U. PY - 2008 DA - 2008// TI - CTLA-4 blockade confers lymphocyte resistance to regulatory T-cells in advanced melanoma: surrogate marker of efficacy of tremelimumab? JO - Clin Cancer Res VL - 14 UR - https://doi.org/10.1158/1078-0432.CCR-07-4797 DO - 10.1158/1078-0432.CCR-07-4797 ID - Menard2008 ER - TY - JOUR AU - Coana, Y. P. AU - Poschke, I. AU - Gentilcore, G. AU - Mao, Y. AU - Nystrom, M. AU - Hansson, J. PY - 2013 DA - 2013// TI - Ipilimumab treatment results in an early decrease in the frequency of circulating granulocytic myeloid-derived suppressor cells as well as their arginase1 production JO - Cancer Immunol Res VL - 1 UR - https://doi.org/10.1158/2326-6066.CIR-13-0016 DO - 10.1158/2326-6066.CIR-13-0016 ID - Coana2013 ER - TY - JOUR AU - Yang, A. AU - Kendle, R. F. AU - Ginsberg, B. A. PY - 2010 DA - 2010// TI - CTLA-4 blockade with ipilimumab increases peripheral CD8+ T cells: correlation with clinical outcomes JO - J Clin Oncol UR - https://doi.org/10.1200/jco.2010.28.15_suppl.2555 DO - 10.1200/jco.2010.28.15_suppl.2555 ID - Yang2010 ER - TY - JOUR AU - Robert, L. AU - Tsoi, J. AU - Wang, X. AU - Emerson, R. AU - Homet, B. AU - Chodon, T. PY - 2014 DA - 2014// TI - CTLA4 blockade broadens the peripheral T-cell receptor repertoire JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2648 DO - 10.1158/1078-0432.CCR-13-2648 ID - Robert2014 ER - TY - JOUR AU - Gabrilovich, D. I. AU - Nagaraj, S. PY - 2009 DA - 2009// TI - Myeloid-derived suppressor cells as regulators of the immune system JO - Nat Rev Immunol VL - 9 UR - https://doi.org/10.1038/nri2506 DO - 10.1038/nri2506 ID - Gabrilovich2009 ER - TY - JOUR AU - Youn, J. I. AU - Gabrilovich, D. I. PY - 2010 DA - 2010// TI - The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity JO - Eur J Immunol VL - 40 UR - https://doi.org/10.1002/eji.201040895 DO - 10.1002/eji.201040895 ID - Youn2010 ER - TY - JOUR AU - Marvel, D. AU - Gabrilovich, D. I. PY - 2015 DA - 2015// TI - Myeloid-derived suppressor cells in the tumor microenvironment: expect the unexpected JO - J Clin Invest VL - 125 UR - https://doi.org/10.1172/JCI80005 DO - 10.1172/JCI80005 ID - Marvel2015 ER - TY - JOUR AU - Kumar, V. AU - Patel, S. AU - Tcyganov, E. AU - Gabrilovich, D. I. PY - 2016 DA - 2016// TI - The nature of myeloid-derived suppressor cells in the tumor microenvironment JO - Trends Immunol VL - 37 UR - https://doi.org/10.1016/j.it.2016.01.004 DO - 10.1016/j.it.2016.01.004 ID - Kumar2016 ER - TY - JOUR AU - Almand, B. AU - Clark, J. I. AU - Nikitina, E. AU - Beynen, J. AU - English, N. R. AU - Knight, S. C. PY - 2001 DA - 2001// TI - Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer JO - J Immunol VL - 166 UR - https://doi.org/10.4049/jimmunol.166.1.678 DO - 10.4049/jimmunol.166.1.678 ID - Almand2001 ER - TY - JOUR AU - Diaz-Montero, C. M. AU - Salem, M. L. AU - Nishimura, M. I. AU - Garrett-Mayer, E. AU - Cole, D. J. AU - Montero, A. J. PY - 2008 DA - 2008// TI - Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin–cyclophosphamide chemotherapy JO - Cancer Immunol Immunother VL - 58 UR - https://doi.org/10.1007/s00262-008-0523-4 DO - 10.1007/s00262-008-0523-4 ID - Diaz-Montero2008 ER - TY - JOUR AU - Solito, S. AU - Falisi, E. AU - Diaz-Montero, C. M. AU - Doni, A. AU - Pinton, L. AU - Rosato, A. PY - 2011 DA - 2011// TI - A human promyelocytic-like population is responsible for the immune suppression mediated by myeloid-derived suppressor cells JO - Blood VL - 118 UR - https://doi.org/10.1182/blood-2010-12-325753 DO - 10.1182/blood-2010-12-325753 ID - Solito2011 ER - TY - JOUR AU - Filipazzi, P. AU - Valenti, R. AU - Huber, V. AU - Pilla, L. AU - Canese, P. AU - Iero, M. PY - 2007 DA - 2007// TI - Identification of a new subset of myeloid suppressor cells in peripheral blood of melanoma patients with modulation by a granulocyte-macrophage colony-stimulation factor-based antitumor vaccine JO - J Clin Oncol VL - 25 UR - https://doi.org/10.1200/JCO.2006.08.5829 DO - 10.1200/JCO.2006.08.5829 ID - Filipazzi2007 ER - TY - JOUR AU - Poschke, I. AU - Mougiakakos, D. AU - Hansson, J. AU - Masucci, G. V. AU - Kiessling, R. PY - 2010 DA - 2010// TI - Immature immunosuppressive CD14+HLA-DR−/low cells in melanoma patients are Stat3hi and overexpress CD80, CD83, and DC-sign JO - Cancer Res VL - 70 UR - https://doi.org/10.1158/0008-5472.CAN-09-3767 DO - 10.1158/0008-5472.CAN-09-3767 ID - Poschke2010 ER - TY - JOUR AU - Filipazzi, P. AU - Huber, V. AU - Rivoltini, L. PY - 2011 DA - 2011// TI - Phenotype, function and clinical implications of myeloid-derived suppressor cells in cancer patients JO - Cancer Immunol Immunother VL - 61 UR - https://doi.org/10.1007/s00262-011-1161-9 DO - 10.1007/s00262-011-1161-9 ID - Filipazzi2011 ER - TY - JOUR AU - Gros, A. AU - Turcotte, S. AU - Wunderlich, J. R. AU - Ahmadzadeh, M. AU - Dudley, M. E. AU - Rosenberg, S. A. PY - 2012 DA - 2012// TI - Myeloid cells obtained from the blood but not from the tumor can suppress T-cell proliferation in patients with melanoma JO - Clin Cancer Res VL - 18 UR - https://doi.org/10.1158/1078-0432.CCR-12-1108 DO - 10.1158/1078-0432.CCR-12-1108 ID - Gros2012 ER - TY - JOUR AU - Jordan, K. R. AU - Amaria, R. N. AU - Ramirez, O. AU - Callihan, E. B. AU - Gao, D. AU - Borakove, M. PY - 2013 DA - 2013// TI - Myeloid-derived suppressor cells are associated with disease progression and decreased overall survival in advanced-stage melanoma patients JO - Cancer Immunol Immunother VL - 62 UR - https://doi.org/10.1007/s00262-013-1475-x DO - 10.1007/s00262-013-1475-x ID - Jordan2013 ER - TY - JOUR AU - Rudolph, B. M. AU - Loquai, C. AU - Gerwe, A. AU - Bacher, N. AU - Steinbrink, K. AU - Grabbe, S. PY - 2014 DA - 2014// TI - Increased frequencies of CD11b+CD33+CD14+HLA-DR low myeloid-derived suppressor cells are an early event in melanoma patients JO - Exp Dermatol VL - 23 UR - https://doi.org/10.1111/exd.12336 DO - 10.1111/exd.12336 ID - Rudolph2014 ER - TY - JOUR AU - Weide, B. AU - Martens, A. AU - Zelba, H. AU - Stutz, C. AU - Derhovanessian, E. AU - Giacomo, A. M. PY - 2014 DA - 2014// TI - Myeloid-derived suppressor cells predict survival of patients with advanced melanoma: comparison with regulatory T Cells and NY-ESO-1- or Melan-A-specific T cells JO - Clin Cancer Res VL - 20 UR - https://doi.org/10.1158/1078-0432.CCR-13-2508 DO - 10.1158/1078-0432.CCR-13-2508 ID - Weide2014 ER - TY - JOUR AU - Tarhini, A. A. AU - Butterfield, L. H. AU - Shuai, Y. AU - Gooding, W. E. AU - Kalinski, P. AU - Kirkwood, J. M. PY - 2012 DA - 2012// TI - Differing patterns of circulating regulatory T cells and myeloid-derived suppressor cells in metastatic melanoma patients receiving anti-CTLA4 antibody and interferon-α or TLR-9 agonist and GM-CSF with peptide vaccination JO - J Immunother VL - 35 UR - https://doi.org/10.1097/CJI.0b013e318272569b DO - 10.1097/CJI.0b013e318272569b ID - Tarhini2012 ER - TY - JOUR AU - Coaña, Y. P. AU - Masucci, G. AU - Hansson, J. AU - Kiessling, R. PY - 2014 DA - 2014// TI - Myeloid-derived suppressor cells and their role in CTLA-4 blockade therapy JO - Cancer Immunol Immunother VL - 63 UR - https://doi.org/10.1007/s00262-014-1570-7 DO - 10.1007/s00262-014-1570-7 ID - Coaña2014 ER - TY - JOUR AU - Meyer, C. AU - Cagnon, L. AU - Costa-Nunes, C. M. AU - Baumgaertner, P. AU - Montandon, N. AU - Leyvraz, L. PY - 2014 DA - 2014// TI - Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab JO - Cancer Immunol Immunother VL - 63 UR - https://doi.org/10.1007/s00262-013-1508-5 DO - 10.1007/s00262-013-1508-5 ID - Meyer2014 ER - TY - JOUR AU - Liakou, C. I. AU - Kamat, A. AU - Tang, D. N. AU - Chen, H. PY - 2008 DA - 2008// TI - CTLA-4 blockade increases IFNγ-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients JO - Proc Natl Acad Sci USA UR - https://doi.org/10.1073/pnas.0806075105 DO - 10.1073/pnas.0806075105 ID - Liakou2008 ER - TY - JOUR AU - Goff, S. L. AU - Robbins, P. F. AU - El-Gamil, M. AU - Rosenberg, S. A. PY - 2009 DA - 2009// TI - No correlation between clinical response to CTLA-4 blockade and presence of NY-ESO-1 antibody in patients with metastatic melanoma JO - J Immunother VL - 32 UR - https://doi.org/10.1097/CJI.0b013e3181affbf0 DO - 10.1097/CJI.0b013e3181affbf0 ID - Goff2009 ER - TY - JOUR AU - Weber, J. S. AU - Hamid, O. AU - Chasalow, S. D. AU - Wu, D. Y. AU - Parker, S. M. AU - Galbraith, S. PY - 2012 DA - 2012// TI - Ipilimumab increases activated T cells and enhances humoral immunity in patients with advanced melanoma JO - J Immunother VL - 35 UR - https://doi.org/10.1097/CJI.0b013e31823aa41c DO - 10.1097/CJI.0b013e31823aa41c ID - Weber2012 ER - TY - JOUR AU - Yuan, J. AU - Gnjatic, S. AU - Li, H. AU - Powel, S. AU - Gallardo, H. F. AU - Ritter, E. PY - 2008 DA - 2008// TI - CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit JO - Proc Natl Acad Sci USA VL - 105 UR - https://doi.org/10.1073/pnas.0810114105 DO - 10.1073/pnas.0810114105 ID - Yuan2008 ER - TY - JOUR AU - Yuan, J. AU - Adamow, M. AU - Ginsberg, B. A. AU - Rasalan, T. S. AU - Ritter, E. AU - Gallardo, H. F. PY - 2011 DA - 2011// TI - Integrated NY-ESO-1 antibody and CD8+ T-cell responses correlate with clinical benefit in advanced melanoma patients treated with ipilimumab JO - Proc Natl Acad Sci USA VL - 108 UR - https://doi.org/10.1073/pnas.1110814108 DO - 10.1073/pnas.1110814108 ID - Yuan2011 ER -